Artivion EMEA’s Post

The interim analysis of the PERSEVERE trial suggests that the use of AMDS lowers 30-day major adverse events (MAEs) in Acute DeBakey Type I dissection patients presenting with malperfusion. Dr. Wilson Y. Szeto, MD talks about the value of AMDS adding minimal time and complexity to the procedure. Learn more about the PERSEVERE US IDE Study 30-Day Results: https://bit.ly/440G7hU #AMDS #cardiothoracicsurgery #PERSEVERE #AorticSurgery #ArtivionEMEA

To view or add a comment, sign in

Explore topics